SUPN stock news · Supernus Pharmaceuticals
Get alerts for SUPN
Follow Supernus Pharmaceuticals (SUPN) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for SUPNSupernus Pharmaceuticals shares details from their earnings call for the third quarter of 2026.
Good for SUPNSupernus's third-quarter sales rose 18%, and it raised its 2026 forecast. Growing drug sales make the news positive, though the Indivior merger is still pending.
Supernus Pharmaceuticals, Inc. will share its third-quarter results on October 29, 2026, after the market closes.
NeutralSupernus set a date to report its third-quarter results, but gave no figures or business update. The filing does not change how we read the company.
Indivior Pharmaceuticals shared news about its merger with Supernus Pharmaceuticals and some legal issues.
NeutralSupernus investors challenged merger disclosures, and the filing says complaints could delay the deal. Supernus denies wrongdoing and added details to limit delay risk.
Complete Transcript of Indivior's Earnings Call for Q2 2026 Released.
Good for SUPNSupernus is merging with Indivior, which will enhance its market position and financial metrics as part of the combined entity.
Q2 2026 results delivered by Supernus Pharmaceuticals: Complete earnings call transcript available.
Good for SUPNSupernus Pharmaceuticals has announced a merger with Indivior Pharmaceuticals, which is expected to create a leading CNS-focused biopharmaceutical company. This merger is anticipated to generate $125 million in annual cost synergies and significantly enhance the combined company's portfolio and growth potential, making it a highly positive development for both companies.
Don't overlook these three health care stocks this quarter that could prove to be valuable.
Good for SUPNSupernus Pharmaceuticals is merging with Indivior Pharmaceuticals, potentially increasing its market share and product offerings.